title: Long-lasting results with hydroxylapatite (Radiesse) facial filler.
abstract: BACKGROUND
  This study examined the patient satisfaction and longevity of Radiesse, a calcium hydroxylapatite compound, as a facial soft-tissue filler for the glabellar lines, the lips, the nose, the face, and the infraorbital region.
  
  
  METHODS
  Radiesse, 0.5 to 2.0 ml, was injected into the designated area in each of the 40 Argentinian male and female patients in the study, using a fine needle. The age range of the patients was 25 to 60 years.
  
  
  RESULTS
  Patients were observed over a period of 18 months. No systemic effects, no immunologic responses, and minimal adverse events (ecchymosis and hematoma in 5 percent of the subjects) occurred with the treatment. In the patient satisfaction survey, 87 percent of the patients rated their level of satisfaction as acceptable or better.
  
  
  CONCLUSIONS
  Radiesse was shown to be a highly effective, long-lasting material for facial soft-tissue augmentation. The safe and well-tolerated compound drew high marks in patient satisfaction. A precise injection technique helped minimize potential effects such as nodule formation and helped avoid persistent overcorrection, livid coloring, and asymmetry. Radiesse can be considered a very good option for an aesthetic soft-tissue facial filler when real volumetric augmentation is needed.
authors.affiliation: University of Buenos Aires, Argentina. pjacovella@elsitio.net
authors.forename: Patricio F
authors.initials: PF
authors.lastname: Jacovella
authors.forename: Claudia B
authors.initials: CB
authors.lastname: Peiretti
authors.forename: Diego
authors.initials: D
authors.lastname: Cunille
authors.forename: Mauricio
authors.initials: M
authors.lastname: Salzamendi
authors.forename: Sophia Asiu
authors.initials: SA
authors.lastname: Schechtel
mesh_terms: D000328:Adult; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003357:Cosmetic Techniques / Q000009:adverse effects; D017886:Durapatite / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005145:Face; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D017060:Patient Satisfaction; D012060:Rejuvenation; D015595:Skin Aging; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D017886:Durapatite